Testing urine biomarkers for chronic kidney disease progression
Official title: Urinary Tubular Biomarkers for Chronic Kidney Disease
Run by Erasmus Medical Center · NCT06732349 · Data updated 2026-11-12
This study is testing a new urine test to see if it can better predict how chronic kidney disease will progress in people with stage 3 CKD.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 556 (estimated) |
| Sponsor | Erasmus Medical Center Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Rotterdam, South Holland) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 2029 |
| Study ends | December 2029 |
| Registry record updated | August 7, 2025 |
| Trial ID | NCT06732349 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults diagnosed with chronic kidney disease stage 3.
✕Probably not a fit
Patients with active glomerulonephritis, kidney transplant recipients, or those undergoing chemotherapy or immunotherapy for malignancy may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to develop a high-throughput tubular test panel that assesses urine biomarkers to improve the prediction of chronic kidney disease (CKD) progression. Currently, CKD diagnosis relies on glomerular function tests, but this study focuses on tubular function, which is crucial for understanding disease progression. By analyzing urine samples already collected as part of standard care, the study will compare the performance of the new tubular test panel against existing methods. The goal is to enable earlier initiation of kidney-protective treatments for patients with CKD stage 3.
Why it matters
Potential benefit: If successful, this study could lead to more accurate predictions of CKD progression and timely interventions for patients.
How similar studies have gone: Other studies have suggested that focusing on tubular function may enhance the understanding of CKD progression, indicating this approach has potential but is still being explored.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic kidney disease stage 3 (eGFR 30-59ml/min) Exclusion Criteria: * Active glomerulonephritis treated with immunosuppression * Kidney transplant recipient * Current treatment with chemo- or immunotherapy for malignancy
Where it's running
-
Erasmus MC
Rotterdam, South Holland, Netherlands Recruiting
Study contacts
- Study coordinator: Sebastian Beckmann, MD
- Email: s.beckmann@erasmusmc.nl
- Phone: +31639022349
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Replacing part of dietary protein with red meat in people with stage 3 chronic kidney disease
This study will test whether swapping some dietary protein for red meat changes levels of uremic toxins like TMAO in adults with stage 3 chronic kidney disease.
-
Automated glucose control's effect on kidney health in diabetes
This study is testing if a new automated way to control blood sugar can improve kidney health in adults with type 2 diabetes and early kidney disease.
-
Investigating AION-301 for Chronic Kidney Disease
This study is testing a new treatment called AION-301 to see if it can help adults with Stage 3 Chronic Kidney Disease feel better and manage their symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.